(Q44888492)

7 December 2017

title

Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series (English)

1 reference

Pleomorphic xanthoastrocytoma

7 December 2017

main subject

1 reference

Marc C Chamberlain

1

1 reference

7 December 2017

publication date

12 June 2013

1 reference

Journal of Neuro-Oncology

7 December 2017

published in

1 reference

7 December 2017

volume

114

1 reference

7 December 2017

issue

2

1 reference

7 December 2017

page(s)

237-240

1 reference

Patterns of care and outcomes of patients with pleomorphic xanthoastrocytoma: a SEER analysis

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1176-5

Pleomorphic xanthoastrocytoma: MR imaging findings in 19 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1176-5

Pleomorphic xanthoastrocytoma: magnetic resonance imaging findings in a series of cases with histopathological confirmation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1176-5

Malignant potential of pleomorphic xanthoastrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1176-5

Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1176-5

Prognostic factors for survival in adult patients with cerebral low-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1176-5

To BRAF or not to BRAF: is that even a question anymore?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1176-5

BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1176-5

Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1176-5

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1176-5

BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1176-5

The molecular biology of WHO grade II gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1176-5

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1176-5

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1176-5

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1176-5

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1176-5

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23756728

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-013-1176-5

1 reference

release_6q7hkh65urdxzgvgxdlj25muem

7 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6q7hkh65urdxzgvgxdlj25muem

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference